Recently, DT2216, a Bcl-xL PROteolysis-TArgeting Chimera (PROTAC) derived from ABT-263, has been reported to be a potent inhibitor of different forms of cancer and with low toxicity versus platelets. This evidence concerns the gene BCL2L1 and cancer.